Chris McHugh Joins Zeus as Senior Vice President of Integrated Supply Chain

Zeus, a world leader in polymer extrusion and catheter manufacturing, is pleased to announce the appointment of Chris McHugh as the Senior Vice President of Integrated Supply Chain, a newly created role. McHugh is a pivotal addition to the leadership team, overseeing end-to-end operations across Zeus’ network of manufacturing facilities.

In this critical role, Chris McHugh will drive operational improvements across the company’s global network, focusing on embedding best-in-class operational excellence, safety, and efficiency principles throughout the organization. He will support the company’s growth objectives by establishing strong operating system processes and standards across the organization, developing and sustaining robust customer relationships, and building, managing, and developing a disciplined, focused, and outcomes-driven operations team with a culture of continuous improvement.

“We are confident that Chris’s leadership and vision will significantly contribute to our operational success and help to accelerate our growth trajectory,” says CEO Paddy O’Brien. “His addition to our team underscores our commitment to excellence and innovation in our supply chain operations and, ultimately, delivering exceptional value to our customers.”

Chris McHugh brings extensive experience in operations management, with a proven track record of leading high-performing teams and implementing transformative initiatives. Most recently, he served as Vice President of Operations at Cadence, Inc., a full-service medical device manufacturer and supplier. His expertise in optimizing processes and driving operational efficiency will be invaluable as Zeus expands its capabilities.

McHugh holds a Bachelor of Science in Mathematics and Physics from Michigan Technological University, a Master of Science in Electrical Engineering from the University of Michigan – Ann Arbor, and a postgraduate executive education in International Business from Columbia Business School.

“I am honored to join Zeus and contribute to its long-standing legacy of innovation and excellence,” said McHugh. “I look forward to working with this talented team to optimize our business processes and operational network to deliver world-class products and customer satisfaction.”

SourceZeus

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.